Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2012 |
| gptkbp:ATCCode |
L04AA29
|
| gptkbp:brand |
gptkb:Xeljanz
|
| gptkbp:CASNumber |
540737-29-9
|
| gptkbp:contraindication |
active tuberculosis
serious infections |
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
3 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C16H20N6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
tofacitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
Janus kinase inhibitor
|
| gptkbp:metabolism |
liver (CYP3A4, CYP2C19)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
40%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
headache hypertension infections increased cholesterol |
| gptkbp:synonym |
gptkb:CP-690,550
|
| gptkbp:usedFor |
gptkb:psoriatic_arthritis
ulcerative colitis rheumatoid arthritis |
| gptkbp:bfsParent |
gptkb:JAK-STAT_signaling_pathway
gptkb:protein_tyrosine_kinases gptkb:JAK3 gptkb:DMARDs |
| gptkbp:bfsLayer |
7
|